Urothelial Carcinoma
Urothelial Carcinoma
Advertisement
Emily MenendezUpper Tract Urothelial Carcinoma | September 22, 2023
The novel nomogram demonstrated perfect performance in discrimination ability and clinical net benefit.
Read More
Zachary BessetteAdvanced Urothelial Carcinoma | September 22, 2023
The phase 3 KEYNOTE-A39/EV-302 study has met its dual primary end points of OS and PFS in advanced or metastatic UC.
Ivan de Kouchkovsky, MDAdvanced Urothelial Carcinoma | September 19, 2023
Dr. de Kouchkovsky highlights survival and response rates after ICIs and EV for patients with squamous histology.
Ivan de Kouchkovsky, MDAdvanced Urothelial Carcinoma | September 19, 2023
Dr. de Kouchkovsky explains studying the impact of squamous histology on clinical outcomes in mUC after ICIs or EV.
Emily MenendezAdvanced Urothelial Carcinoma | September 15, 2023
The positive results were consistent with findings from the primary analysis, such as PFS and overall response benefit.
Anke Richters, PhDUrothelial Carcinoma | September 12, 2023
Anke Richters, PhD, discusses how not reporting primary end point changes in clinical trials can lead to issues.
Emily MenendezMuscle Invasive Urothelial Carcinoma | September 8, 2023
Perioperative durvalumab with gemcitabine/cisplatin in patients with resectable MIBC resulted in high EFS and OS at 2 years.
Emily MenendezUpper Tract Urothelial Carcinoma | September 8, 2023
Older patients over 70 years of age need improved care and management of UTUC to improve their outcomes.
Raj Satkunasivam, MD, MS, FRCSCNon-Muscle Invasive Urothelial Carcinoma | September 8, 2023
Dr. Satkunasivam shares the inspiration for combining sasanlimab with BCG in patients with high-risk, BCG-naïve NMIBC.
Akhil Abraham Saji, MDLocalized Prostate Cancer | September 5, 2023
The da Vinci Single Port platform allows robot-assisted surgical procedures with the same precision as multiport techniques.
Zachary BessetteAdvanced Urothelial Carcinoma | August 30, 2023
Multiple genitourinary oncology therapies are in the spotlight this week, with new US FDA indications on the horizon.
Sandip Prasad, MD, MPhilNon-Muscle Invasive Urothelial Carcinoma | August 30, 2023
Dr. Prasad provides overviews of ATLAS and ENVISION and opines on whether UGN-102 is a practice-ready alternative to TURBT.
Emily MenendezAdvanced Urothelial Carcinoma | August 29, 2023
Somatic alterations in DDR genes are common in patients with advanced urothelial cancer.
Guru P. Sonpavde, MDMuscle Invasive Urothelial Carcinoma | August 24, 2023
Dr. Sonpavde expounds on the current state and momentum of research efforts to advance treatment strategies in MIBC.
Emily MenendezUpper Tract Urothelial Carcinoma | August 17, 2023
Patients who had initiated AC 90 days after RNU were examined to determine a relation between treatment efficacy and timing.
Leah LawrenceNon-Muscle Invasive Urothelial Carcinoma | August 17, 2023
Several urologists weigh in on BCG, its role in NMIBC treatment, shortages, and strategies to treat BCG-unresponsive disease.
Ajitha Kommalapati, MDASCO 2023 | August 15, 2023
Dr. Kommalapati shares her thoughts on the association between tumor-informed MRD and clinical outcomes for MIBC.
Emily MenendezUrothelial Carcinoma | August 9, 2023
Patients with cN+ m0 BCa had similar survival outcomes whether treated with surgery or radical therapy.
Raj Satkunasivam, MD, MS, FRCSCMuscle Invasive Urothelial Carcinoma | August 9, 2023
Dr. Satkunasivam details the RAD VACCINE MIBC trial, an evaluation of the efficacy and safety of neoadjuvant sasanlimab.
Raj Satkunasivam, MD, MS, FRCSCMuscle Invasive Urothelial Carcinoma | August 9, 2023
Dr. Satkunasivam explains the momentum for an IO-plus-radiation strategy in MIBC, as well as the potential of sasanlimab.
Advertisement
Advertisement
Advertisement